BRUKINSA patients can call the myBeiGene® patient support program to talk to a dedicated nurse: 1-833-BEIGENE (1-833-234-4363)
BRUKINSA® (zanubrutinib) has been shown to block 100% of BTK in blood cells and 94% to 100% of BTK in lymph nodes when taken at the recommended total daily dose of 320 mg. The signiﬁcance of blocking up to 100% of BTK on treatment responses has not been established.BRUKINSA is for adults with marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.
BRUKINSA was approved based on response rate. There is ongoing evaluation to confirm clinical benefit for this use. It is not known if BRUKINSA is safe and effective in children.
Bruton’s tyrosine kinase (BTK) is a protein that has been linked to MZL.
To meet your individual needs, myBeiGene pairs you with a dedicated Oncology Nurse Advocate who will personalize support for you and your caregivers during your treatment with BRUKINSA.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking BRUKINSA with certain other medications may affect how BRUKINSA works and can cause side effects.
These are not all the possible side effects of BRUKINSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
BRUKINSA is a prescription medicine used to treat adults with:
It is not known if BRUKINSA is safe and effective in children.